Melanoma vaccine - Progenics
Alternative Names: BMS 248479; GMK vaccine; MGV vaccineLatest Information Update: 23 Sep 2021
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Class Cancer vaccines
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 16 Jun 2020 Progenics Pharmaceuticals was acquired by Lantheus Holdings
- 09 Aug 2007 Discontinued - Phase-III for Malignant melanoma in USA, New Zealand, United Kingdom, South America, Europe, South Africa, Australia (SC)
- 01 Dec 2005 The GMK vaccine is still in active development